AstraZeneca has officially appointed Iskra Reic as its new Executive Vice President, International.
Iskra will be responsible for developing the pharmaceutical company's strategy, while also supporting its sustainable global growth across Chinese, Asian, Middle Eastern, African, Latin American, Australian and New Zealand markets.
Ms Reic joined the company in 2001, and has held leadership positions within AstraZeneca across the globe.
In 2017, she was named the Executive Vice President for Europe and Canada — which placed her in AstraZeneca's Senior Executive Team.
Recently, Iskra was instrumental in the launch of AstraZeneca's vaccines and immune therapies unit, which focuses on both the early-stage development of the company's immunotherapy pipeline, as well as the company's late-stage portfolio.
She was also responsible for the development of strategic partnerships, acquisitions and commecial operations.
CEO of AstraZeneca, Pascal Soriot, commented: “Iskra is a highly accomplished leader with extensive international experience across multiple disciplines and a track record of improving patient access to our innovative and life-changing medicines. Her experience building partnerships will be invaluable in taking the fast-growing International region forward.”
Iskra Reic, Executive Vice President, International, said: “It's a privilege to lead this broad, diverse and innovative region as we deliver the next wave of science and innovative medicines. I look forward to working with our partners, stakeholders and colleagues to improve the lives of millions of people around the world with our leading medicines and vaccines.”
Iskra succeeds Leon Wang who is on extended leave from the Company while under investigation in China.